文献速递免疫规划

比较皮内与肌内接种BNT162b2 XBB.1.5疫苗在老年人中的免疫原性:等效剂量研究

Comparing the immunogenicity of intradermal and intramuscular vaccination of elderly with BNT162b2 XBB.1.5: An equivalent dose study.
PubMed 文献 · Vaccine · 2025-09-15

2023年11月至12月,48名75-86岁成人随机分组,分别接受20μg皮内、20μg肌内或标准30μg肌内BNT162b2 XBB.1.5疫苗。接种后28天,三组血清抗Spike IgG和ACE2结合抑制能力无差异;皮内接种局部不良事件均为轻度自限性,肌内接种反应原性更低。

要点

  • 皮内与肌内接种20μg BNT162b2 XBB.1.5疫苗在老年人中抗体水平和功能无差异。
  • 肌内接种的反应原性低于皮内接种,皮内接种局部不良事件均为轻度自限性。
  • 三组血清和黏膜IgG、IgA及ACE2抑制反应呈平行趋势。

核心结论

  • 在老年人中,皮内与肌内接种20μg BNT162b2 XBB.1.5疫苗后抗体水平和功能无差异,而肌内接种的反应原性低于皮内接种。

研究设计与样本

  • 2023年11月至12月,48名75-86岁成人按1:1:1随机分为三组(每组16人),分别接受20μg皮内注射(微针)、20μg肌内注射或标准30μg肌内注射BNT162b2 XBB.1.5疫苗(NCT05977127)。

主要发现

  • 接种后28天,三组血清抗Spike IgG和ACE2结合抑制能力无差异。
  • 纵向分析显示三组血清和黏膜IgG、IgA及ACE2抑制反应呈平行趋势。
  • 皮内接种诱导了与肌内接种不同的血液转录组谱,但未发现差异调控的特异性通路。
  • 所有皮内接种参与者出现轻度自限性局部不良事件,而肌内接种参与者则相反。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Aging coincides with a decline in immune functioning, whereby elderly become less responsive to vaccination. Alternative vaccination strategies, including administration into the skin, may improve immunogenicity and efficacy. Here, we investigated the immunogenicity of intradermal (ID) administration of a fractional dose of a COVID-19 vaccine in elderly (75 years and older) compared to standard intramuscular (IM) administration of an equivalent dose. METHODS: Between November and December 2023, 48 adults aged 75-86 were randomized (1:1:1, n = 16/group) to receive either 20 μg of the BNT162b2 XBB.1.5 vaccine via ID injection, using a microneedle, or 20 μg via IM injection, or the standard 30 μg dose via IM injection (NCT05977127). The primary endpoint was the geometric mean concentration (GMC) of SARS-CoV-2 Spike-specific IgG at day 28 post-vaccination. Secondary endpoints included the serum ACE2 binding inhibition at day 28, as well as incidence of local and systemic adverse events (AEs), recorded during the first 28 days post-vaccination. Exploratory outcomes included longitudinal immunogenicity assessments in serum and nasal mucosal lining fluid, on days 0, 28 and 122 and whole blood transcriptome profiling on day 0 and 1. RESULTS: At day 28 post-vaccination, no differences were found in serum anti-Spike IgG and ACE2 binding inhibition capacity between all three groups. Longitudinal analysis revealed parallel trends across groups in serum and mucosal IgG, IgA and ACE2 inhibition response. While ID vaccination induced a distinct blood transcriptomic profile compared to IM administration, no specific pathways were found that were differentially regulated. Mild and self-limiting local AEs were observed in all ID vaccinated participants, in contrast to IM vaccinated participants. CONCLUSION: No differences were found in antibody level and functionality following ID and IM administration of 20 μg BNT162b2 XBB.1.5 vaccine in elderly, while IM administration was less reactogenic than ID administration.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. van Beek LF, He X, Koks MS, et al. Comparing the immunogenicity of intradermal and intramuscular vaccination of elderly with BNT162b2 XBB.1.5: An equivalent dose study. Vaccine. 2025. PMID: 40957304. doi:10.1016/j.vaccine.2025.127749

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。